BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26061388)

  • 1. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist.
    Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H
    J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
    Fauber BP; Gobbi A; Robarge K; Zhou A; Barnard A; Cao J; Deng Y; Eidenschenk C; Everett C; Ganguli A; Hawkins J; Johnson AR; La H; Norman M; Salmon G; Summerhill S; Ouyang W; Tang W; Wong H
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2907-12. PubMed ID: 26048793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reversed sulfonamide series of selective RORc inverse agonists.
    van Niel MB; Fauber BP; Cartwright M; Gaines S; Killen JC; René O; Ward SI; de Leon Boenig G; Deng Y; Eidenschenk C; Everett C; Gancia E; Ganguli A; Gobbi A; Hawkins J; Johnson AR; Kiefer JR; La H; Lockey P; Norman M; Ouyang W; Qin A; Wakes N; Waszkowycz B; Wong H
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5769-5776. PubMed ID: 25453817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists.
    Fauber BP; Gobbi A; Savy P; Burton B; Deng Y; Everett C; La H; Johnson AR; Lockey P; Norman M; Wong H
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4109-13. PubMed ID: 26321361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of tertiary sulfonamides as RORc inverse agonists.
    Fauber BP; René O; Burton B; Everett C; Gobbi A; Hawkins J; Johnson AR; Liimatta M; Lockey P; Norman M; Wong H
    Bioorg Med Chem Lett; 2014 May; 24(9):2182-7. PubMed ID: 24685544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists.
    Fauber BP; René O; de Leon Boenig G; Burton B; Deng Y; Eidenschenk C; Everett C; Gobbi A; Hymowitz SG; Johnson AR; La H; Liimatta M; Lockey P; Norman M; Ouyang W; Wang W; Wong H
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3891-7. PubMed ID: 25017032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc).
    Fauber BP; Magnuson S
    J Med Chem; 2014 Jul; 57(14):5871-92. PubMed ID: 24502334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
    Fauber BP; de Leon Boenig G; Burton B; Eidenschenk C; Everett C; Gobbi A; Hymowitz SG; Johnson AR; Liimatta M; Lockey P; Norman M; Ouyang W; René O; Wong H
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6604-9. PubMed ID: 24239186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists.
    Wu XS; Wang R; Xing YL; Xue XQ; Zhang Y; Lu YZ; Song Y; Luo XY; Wu C; Zhou YL; Jiang JQ; Xu Y
    Acta Pharmacol Sin; 2016 Nov; 37(11):1516-1524. PubMed ID: 27374490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.
    Ouvry G; Atrux-Tallau N; Bihl F; Bondu A; Bouix-Peter C; Carlavan I; Christin O; Cuadrado MJ; Defoin-Platel C; Deret S; Duvert D; Feret C; Forissier M; Fournier JF; Froude D; Hacini-Rachinel F; Harris CS; Hervouet C; Huguet H; Lafitte G; Luzy AP; Musicki B; Orfila D; Ozello B; Pascau C; Pascau J; Parnet V; Peluchon G; Pierre R; Piwnica D; Raffin C; Rossio P; Spiesse D; Taquet N; Thoreau E; Vatinel R; Vial E; Hennequin LF
    ChemMedChem; 2018 Feb; 13(4):321-337. PubMed ID: 29327456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist.
    Chen L; Su M; Jin Q; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Liao ZX
    Bioorg Chem; 2022 Feb; 119():105483. PubMed ID: 34906860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties.
    René O; Fauber BP; Barnard A; Chapman K; Deng Y; Eidenschenk C; Everett C; Gobbi A; Johnson AR; La H; Norman M; Salmon G; Summerhill S; Wong H
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4455-4461. PubMed ID: 27524313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
    Kono M; Ochida A; Oda T; Imada T; Banno Y; Taya N; Masada S; Kawamoto T; Yonemori K; Nara Y; Fukase Y; Yukawa T; Tokuhara H; Skene R; Sang BC; Hoffman ID; Snell GP; Uga K; Shibata A; Igaki K; Nakamura Y; Nakagawa H; Tsuchimori N; Yamasaki M; Shirai J; Yamamoto S
    J Med Chem; 2018 Apr; 61(7):2973-2988. PubMed ID: 29510038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-α.
    Doebelin C; He Y; Campbell S; Nuhant P; Kumar N; Koenig M; Garcia-Ordonez R; Chang MR; Roush WR; Lin L; Kahn S; Cameron MD; Griffin PR; Solt LA; Kamenecka TM
    Med Chem; 2019; 15(6):676-684. PubMed ID: 30799793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ.
    Olsson RI; Xue Y; von Berg S; Aagaard A; McPheat J; Hansson EL; Bernström J; Hansson P; Jirholt J; Grindebacke H; Leffler A; Chen R; Xiong Y; Ge H; Hansson TG; Narjes F
    ChemMedChem; 2016 Jan; 11(2):207-16. PubMed ID: 26553345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.
    Song Y; Xue X; Wu X; Wang R; Xing Y; Yan W; Zhou Y; Qian CN; Zhang Y; Xu Y
    Eur J Med Chem; 2016 Jun; 116():13-26. PubMed ID: 27043267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Drug with Lipophilicity-Dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-Related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-Inflammatory Agent.
    Wang Y; Liu H
    J Med Chem; 2018 Dec; 61(23):10412-10414. PubMed ID: 30507131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.
    Schnute ME; Wennerstål M; Alley J; Bengtsson M; Blinn JR; Bolten CW; Braden T; Bonn T; Carlsson B; Caspers N; Chen M; Choi C; Collis LP; Crouse K; Färnegårdh M; Fennell KF; Fish S; Flick AC; Goos-Nilsson A; Gullberg H; Harris PK; Heasley SE; Hegen M; Hromockyj AE; Hu X; Husman B; Janosik T; Jones P; Kaila N; Kallin E; Kauppi B; Kiefer JR; Knafels J; Koehler K; Kruger L; Kurumbail RG; Kyne RE; Li W; Löfstedt J; Long SA; Menard CA; Mente S; Messing D; Meyers MJ; Napierata L; Nöteberg D; Nuhant P; Pelc MJ; Prinsen MJ; Rhönnstad P; Backström-Rydin E; Sandberg J; Sandström M; Shah F; Sjöberg M; Sundell A; Taylor AP; Thorarensen A; Trujillo JI; Trzupek JD; Unwalla R; Vajdos FF; Weinberg RA; Wood DC; Xing L; Zamaratski E; Zapf CW; Zhao Y; Wilhelmsson A; Berstein G
    J Med Chem; 2018 Dec; 61(23):10415-10439. PubMed ID: 30130103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
    Lu Z; Duan JJ; Xiao H; Neels J; Wu DR; Weigelt CA; Sack JS; Khan J; Ruzanov M; An Y; Yarde M; Karmakar A; Vishwakrishnan S; Baratam V; Shankarappa H; Vanteru S; Babu V; Basha M; Kumar Gupta A; Kumaravel S; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2265-2269. PubMed ID: 31257087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.
    Sun N; Ma X; Zhou K; Zhu C; Cao Z; Wang Y; Xu J; Fu W
    Eur J Med Chem; 2020 Feb; 187():111984. PubMed ID: 31881455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.